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Ethylene glycol monomethyl ether (EGME) is a widely used
industrial solvent known to cause adverse effects to human and
other mammals. Organs with high metabolism and rapid cell
division, such as testes, are especially sensitive to its actions. In
order to gain mechanistic understanding of EGME-induced
toxicity, an untargeted metabolomic analysis was performed in
rats. Male rats were administrated with EGME at 30 and 100
mg/kg/day. At days 1, 4, and 14, serum, urine, liver, and testes
were collected for analysis. Testicular injury was observed at day
14 of the 100 mg/kg/day group only. Nearly 1900 metabolites
across the four matrices were proﬁled using liquid chromatogra-
phy-mass spectrometry/mass spectrometry and gas chromatogra-
phy-mass spectrometry. Statistical analysis indicated that the
most signiﬁcant metabolic perturbations initiated from the early
time points by EGME were the inhibition of choline oxidation,
branched-chain amino acid catabolism, and fatty acid b-oxidation
pathways, leading to the accumulation of sarcosine, dimethylgly-
cine, and various carnitine- and glycine-conjugated metabolites.
Pathway mapping of these altered metabolites revealed that all
the disrupted steps were catalyzed by enzymes in the primary
ﬂavoprotein dehydrogenase family, suggesting that inhibition of
ﬂavoprotein dehydrogenase–catalyzed reactions may represent
the mode of action for EGME-induced toxicity. Similar urinary
and serum metabolite signatures are known to be the hallmarks of
multiple acyl-coenzyme A dehydrogenase deﬁciency in humans,
a genetic disorder because of defects in primary ﬂavoprotein
dehydrogenase reactions. We postulate that disruption of key
biochemical pathways utilizing ﬂavoprotein dehydrogenases in
conjugation with downstream metabolic perturbations collectively
result in the EGME-induced tissue damage.
Key Words: metabolomics; ethylene glycol monomethyl ether;
mode of action.
Ethylene glycol monomethyl ether (EGME) is an industrial
solvent used widely for the production of cellulose acetate,
resins, paints, inks, and stains. It is also used in jet fuels and
hydraulic ﬂuids as an antifreeze. EGME is colorless and
volatile and can be absorbed readily by inhalation and skin
contact. It has been well established that EGME causes toxicity
to several mammalian species including human. Tissues and
organs with rapidly dividing cells and high metabolism, such as
testes and thymus, are known to be particularly vulnerable
(Bagchi and Waxman, 2008; Boatman, 2005; Johanson, 2000).
In human studies, various reports have linked occupational
exposure to EGME with hematological, neurological, and
reproductive tissue abnormalities (Cohen, 1984; Cook et al.,
1982; El-Zein et al., 2002; Larese et al., 1992; Welch and
Cullen, 1988; Welch et al., 1988). In laboratory animals,
reproductive tissue damage, including testicular atrophy and
impairment of female fertility, has been found to be the most
signiﬁcant outcome of EGME treatment (Berndtson and Foote,
1997; Chapin and Lamb, 1984; Dodo et al., 2009; Doe et al.,
1983; Hanley et al., 1984). In addition, EGME can also impact
the immune system, causing decreased thymus weight, thymic
atrophy, and reduced spleen cell number (Exon et al., 1991).
In spite of the substantial EGME literature and the well-
documented histopathological ﬁndings, little has been eluci-
dated about the molecular mechanisms of EGME-induced
toxicity. Transcriptomic analyses have been conducted to un-
derstand gene changes following EGME treatment (Fukushima
et al., 2005; Jindo et al., 2001; Syed and Hecht, 1998; Tirado
et al., 2003; Wang and Chapin, 2000). Among genes regulated
by EGME were various protein kinases and genes associated
with oxidative stress, thus leading to the hypothesis that
EGME-induced apoptosis is mediated through oxidative stress
(Bagchi and Waxman, 2008). However, in these studies, a
single high dose of EGME was used, which could result in
acute cell injury. With the exception of one study (Jindo et al.,
2001), all the transcriptomic analyses of EGME toxicity
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the scope of these data sets. In another well-designed study,
a microarray analysis of the effect of methoxyacetic acid
(MAA), a metabolite of EGME treatment in rats over a time
course, suggested that histone hyperacetylation could be an
underlying cause of the toxicity (Wade et al., 2008).
Biochemical proﬁling, or metabolomics, is a rapidly evolv-
ing technology that has been used increasingly in disease
characterization and drug development. Hence, we attempted
to gain further understanding of the molecular mechanism of
EGME-induced toxicity by an unbiased biochemical proﬁling
approach based on liquid chromatography/mass spectrometry
and gas chromatography/mass spectrometry (LC/MS and GC/
MS). For this study, male rats were treated with two doses of
EGME (30 and 100 mg/kg/day) and vehicle control. Serum,
urine, liver, and testes were collected at days 1, 4, and 14 for
metabolic proﬁle analyses.
MATERIALS AND METHODS
Animal studies. Male Fischer 344 rats of 9 weeks of age used in this study
were from Charles River Japan, Inc. (Atsugi Breeding Center, Tokyo, Japan).
Animals were housed in stainless steel cages in a room that was lit for 12 h
(0700 h–1900 h) daily, ventilated with an air exchange rate of 10–20 times/h,
and maintained at 20C–26C with a relative humidity of 30–70%. Rats were
housed individually in metabolic cages during the period when urine samples
were collected, and urine collection began after transfer to these cages. All
animals were allowed free access to water and food (Charles River Formula 1,
sterilized by radiation; Oriental Yeast Co., Tokyo, Japan) except for a 4-h fasting
period prior to plasma and tissue collection. After a 5-day acclimatization period,
rats were randomly assigned to nine groups (n ¼ 5 for each group) by body
weight. Three groups received EGME at 30 mg/kg/day, three groups received
EGME at 100 mg/kg/day, and the other three groups received a vehicle control
(0.5% carboxymethyl cellulose sodium aqueous solution) by oral gavage. The
initial dosing day was designated as day 0, and various samples were collected at
days 1, 4, and 14. Urine was collected over 24 h with the collection vessels
surrounded by dry ice during the collection period. After urine collection, rats
were maintained under fasting condition for 4 h after which serum samples were
collected. Animals were then euthanized for histopathological examination and
liver and testes harvested. The samples were stored in a freezer at  80C. All
animal study procedures were performed in accordance with the rules of the
Institutional Animal Care and Use Committee at the study facility.
Metabolomic proﬁling platform. The untargeted metabolic proﬁling
platform employed for this analysis was based on a combination of three in-
dependent platforms: ultrahigh-performance liquid chromatography/tandem
mass spectrometry (UHPLC/MS/MS) optimized for basic species, UHPLC/MS/
MS optimized for acidic species, and GC/MS. The details of this platform were
described in a previous publication (Evans et al., 2009).
Data imputation and statistical analysis. After the data were corrected for
minor variation resulting from instrument interday tuning differences (Evans
et al., 2009), the missing values for a given metabolite were imputed with the
observed minimum detection value on the assumption that they were below the
limits of detection. For the convenience of data visualization, the raw area
counts for each metabolite were rescaled by dividing each samples value by the
median value for the speciﬁc metabolite.
Statistical analysis of the data was performed using JMP (SAS, http://
www.jmp.com), a commercial software package, and ‘‘R’’ (http://cran
.r-project.org/), which is a freely available open source software package. A
log transform was applied to the observed relative concentrations for each
metabolite because, in general, the variance increased as a function of
a metabolite’s average response. Welch’s t-tests were performed to compare
data between experimental groups. Multiple comparisons were accounted for
with the false discovery rate (FDR) method, and each FDR was estimated using
q values.
RESULTS
Dose Regimen and Histopathological Observations
In this study, we treated male rats with two doses (30 and
100 mg/kg/day) and selected three time points (days 1, 4, and
14) for analysis. As summarized in Tables 1 and 2, body, liver,
kidney, thymus, epididymis, and testes weights as well as
organ histopathology were examined. At the 30 mg/kg/day
dose, there were no signiﬁcant differences between the treat-
ment and the control groups at all three time points. At the
100 mg/kg/day dose, a signiﬁcant decrease in testis weight was
observed at day 14. Consistent with this ﬁnding, single-cell
necrosis of dividing spermatocytes (stage XIV), decreased
number of spermatocytes, rounded and elongated spermatids
(stages I–VI), and ductal cell debris were observed (Fig. 1).
Another signiﬁcant difference was the decreased thymus
weight at both day 4 and day 14. Also, at the 100 mg/kg/day
dose, decreased number of spermatozoa and cell debris in
epididymal ducts were observed. In addition, slight and tran-
sient decreases in liver and kidney weight were observed at day
4 only. However, no abnormal histopathological changes were
noted in either organ.
Metabolomic Proﬁles and Statistical Analysis
A combination of two LC/MS/MS platforms and a GC/MS
platform were used to proﬁle the metabolites present in the
serum, urine, liver, and testes. The detailed method is described
in a previous publication (Evans et al., 2009). In brief, the
samples were extracted, analyzed over the three MS platforms,
ion peaks matched to standards in a reference library for
structural identiﬁcation, and relative levels quantitated. Across
TABLE 1
Histopathological Findings in Rats Treated with 100 mg/kg/day
of EGME at Day 14. There Were No Pathological Changes in
Other Time Points and with 30 mg/kg/day Doses
Tissue
Number of rats
affected Histopathological changes
Testis 3/5 Single-cell necrosis of dividing
spermatocytes, cell debris in tubules,
decreased number of spermatocytes, round
spermatids, and elongate spermatids
Epididymis 2/5 Decreased number of spermatozoa in duct
and cell debris in duct
Liver 0/5 Within normal limits
Kidney 0/5 Within normal limits
Thymus 0/5 Within normal limits
644 TAKEI ET AL.the four matrices, nearly 1900 metabolites were proﬁled by this
method (391, 575, 422, and 418 metabolites from the serum,
urine, liver, and testes, respectively).
Five rats per experimental group were used in this study. The
changes of the metabolites between EGME-treated groups and
their control at each time point were calculated by the ratio of
their group means. The statistical signiﬁcance of the changes
was analyzed by Welch’s t-test, with p < 0.05 deemed to be
signiﬁcant. In addition, multiple comparisons for this data set
were accounted for with the FDR method, and each FDR was
estimated using q values. The full statistical table is included in
the Supplementary data. After mapping the metabolites into
general biochemical pathways as illustrated in the Kyoto
Encyclopedia of Genes and Genomes (http://www.genome.jp/
kegg/) and analyzing the statistical signiﬁcance (see the
statistical table under Supplementary data), it became clear
that the pathways perturbed by the EGME in the early time
points and persisted throughout the course of the experiment
were those of choline oxidation, branched-chain amino acid
(BCAA) catabolism, and fatty acid b-oxidation.
Choline Oxidation
The catabolism of choline occurs through a series of de-
methylation steps to produce betaine, dimethylglycine, sarco-
sine, and glycine (Fig. 2). In this study, increases of urinary
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FIG. 1. Histopathological observations of the testis in day 14 group.
Representative light micrographs are shown. Seminiferous tubules at stages
XIV (A and B) and I–VI (C and D) from the 100 mg/kg–treated group (B and D)
and the control (A and C) are shown. The dividing spermatocytes are indicated
by arrows. Single-cell necrosis and cell debris in the tubules were observed at
stage XIV (B). Spermatocytes and round and elongate spermatids were decreased
or lost in the 100 mg/kg–treated group (C) compared with the control group (D).
MODE OF ACTION OF EGME-INDUCED TOXICITY 645dimethylglycine and sarcosine were among the most dramatic
changes induced by EGME treatment (Fig. 2). Sarcosine was
elevated signiﬁcantly at day 1 of the 100 mg/kg dose and then
at days 4 and 14 of both doses. Dimethylglycine was elevated
signiﬁcantly at days 4 and 14 of both doses.
Amino Acid Catabolism and Fatty Acid b-Oxidation
Signiﬁcant changes in the isoleucine pathway by EGME
were observed. As shown in a condensed scheme (Fig. 3), the
catabolism of isoleucine produces succinyl-coenzyme A
(CoA), which is further incorporated into the tricarboxylic
acid (TCA) cycle for energy production (The S-pathway).
Alternatively, isoleucine can be degraded by the R-pathway to
produce metabolites. A portion of the R-pathway overlaps with
fatty acid b-oxidation because butyrylglycine, butyrylcarnitine,
and ethylmalonate can be derived from both pathways. In this
study, the levels of 2-methylbutyrylglycine, 3-hydroxy-2-
ethylpropionate, ethylmalonate, and butyrylglycine were in-
creased in the urine following the EGME treatment. In addition,
the levels of butyrylcarnitine, 2-methylbutyrylcarnitine, and 3-
hydroxy-2-ethylpropionate were elevated in the serum, testes,
and liver (Fig. 3). Many of these changes were signiﬁcant as
early as day 4 at both the 30 and the 100 mg/kg doses.
Similar to isoleucine metabolism, leucine catabolism was
altered by EGME treatment. Isovalerylglycine was signiﬁ-
cantly elevated in the urine at day 4 by the 100 mg/kg doses
and at day 14 by both the 30 and the 100 mg/kg doses. The
increase of hydroxyisovaleroylcarnitine was observed in the
testes at day 14 of the 100 mg/kg dose (Fig. 4).
Another signiﬁcant change of EGME treatment was ob-
served in lysine catabolism. In liver, a signiﬁcant increase of
glutarylcarnitine was found at day 14 of the 100 mg/kg group
(Fig. 5). Glutarylcarnitine also showed a trend of increases in
a dose-dependent manner at day 4, although the p values were
slightly beyond the signiﬁcance cutoff of 0.05.
Notable Metabolic Changes at Day 14
Creatine was increased signiﬁcantly in the urine, serum, and
liver. Arginine, guanidinoacetate, and ornithine were also ele-
vated in various matrices, suggesting that the biosynthesis of
creatine was altered following EGME treatment (Fig. 6). These
changes were primarily signiﬁcant at day 14 of the 100 mg/kg/
day group.
Additional metabolites likely associated with cell and tis-
sue damage, including dihydrouracil, pyroglutamine, hydrox-
yproline, and dimethylarginine were found to be elevated by
EGME treatment in various matrices (Fig. 7). Ophthalmate, on
the contrary, was decreased by EGME treatment (Fig. 7).
Dihydrouracil is a catabolite of RNA degradation. Pyroglut-
amine is a posttranslational protein modiﬁcation of N-termini.
Its presence is likely derived from protein degradation.
Hydroxyproline is a marker for collagen degradation. Oph-
thalmate and dimethylarginine are markers for oxidative stress
(Beltowski and Kedra, 2006; Soga et al., 2006). These changes
were mostly observed at day 14 of the 100 mg/kg/day dose.
DISCUSSION
We performed a multidose and multi–time point analysis of
serum, urine, liver, and testicular tissues collected from
EGME-treated rats. The doses and time points were chosen
so that only the last time point of the high-dose group would
display tissue injury by histopathological analysis. By this
experimental design, we hoped to identify EGME’s mechanism
of action and the metabolic effects leading to tissue injury.
Statistical analysis of the data and pathway mapping of the
metabolites clearly found that the primary perturbation by
EGME was centered on the inhibition of choline oxidation,
BCAA catabolism, and fatty acid b-oxidation pathways.
In the choline oxidation pathway, sarcosine was elevated at
day 1 by the 100 mg/kg EGME treatment. At days 4 and14,
dimethylglycine and sarcosine were both increased signiﬁ-
cantly by the 30 and 100 mg/kg EGME. These changes strongly
suggested that the inhibition of the enzymes converting the two
metabolites, dimethylglycine dehydrogenase (DMGDH) and
FIG. 2. Choline oxidation pathway and the box plots of dimethylglycine
and sarcosine in the urine. Asterisk represents statistically signiﬁcant to the
control group. The box represents the middle 50% of the distribution, and upper
and lower ‘‘whiskers’’ represent the entire spread of the data. The hyphen refers
to the mean and the circle the outlier. The name of each metabolite is indicated
on the top of the plot. The y-axis references the median scaled value. The
p values for all comparisons are referenced in Supplementary data and, if less
than 0.05, are marked with an asterisk. GNMT, glycine N-methyltransferase;
SDH, sarcosine dehydrogenase.
646 TAKEI ET AL.sarcosine dehydrogenase (SDH) (Fig. 2), was an early action of
the EGME treatment.
Similarly, many intermediates in the isoleucine and leucine
catabolism were accumulated at the early time points and the
low-dose EGME treatment. As illustrated in Figures 3 and 4,
the catabolism of isoleucine and leucine generates various CoA
intermediates. The CoA intermediates can be rapidly converted
into their corresponding carnitine esters (which can often be
measured in serum and tissues) and/or glycine esters (which
can often be measured in urine). Under normal conditions, the
levels of carnitine and glycine CoA esters are low because the
CoA intermediates are efﬁciently converted to produce acetyl-
CoA and succinyl-CoA, which are incorporated into the TCA
cycle for energy generation. Hence, the serum and urinary
proﬁles of carnitine and glycine metabolites can reﬂect im-
paired BCAA metabolism and have been used as biomarkers
for genetic disorders associated with BCAA metabolic path-
ways (Bennett et al., 1994; Korman, 2006; Tanaka et al.,
1966). The accumulation of 2-methylbutyrylcarnitine and
2-methylbutyrylglycine in the isoleucine catabolic pathway
suggests that short/branched-chain acyl-CoA dehydrogenase,
the enzyme converting 2-methylbutyryl-CoA, was inhibited
by EGME. Consistent with this conclusion, 3-hydroxy-2-
ethylpropionate, ethylmalonate, butyrylglycine, and butyrylcar-
nitine were increased because of the inhibition of the S-pathway,
thus shunting isoleucine into the R-pathway. Similarly, the in-
creases of isovalerylglycine and hydroxyisovaleroylcarnitine in
the leucine catabolic pathway suggested that isovaleryl-CoA
dehydrogenase was inhibited by EGME.
Although choline oxidation and isoleucine/leucine catabo-
lism were not directly associated in a metabolic cascade, the
fact that the pathways were simultaneously affected by EGME
suggested that they shared a common linkage. Upon examin-
ing the EGME-inhibited enzymes in the pathways, it became
apparent that they all belonged to a small enzyme family of
primary ﬂavoprotein dehydrogenases with ﬂavin adenine
dinucleotide (FAD) as the prosthetic factor. This family of
enzymes is involved in fatty acid b-oxidation (short-, medium-,
long-, and very long–chain acyl-CoA dehydrogenases [LCAD]),
amino acid metabolism (isovaleryl-CoA dehydrogenase for
FIG. 3. Isoleucine metabolism and the box plots of isoleucine catabolites altered by EGME treatment. Asterisk represents statistically signiﬁcant to the control
group. SBCAD, short/branched-chain acyl-CoA dehydrogenase.
MODE OF ACTION OF EGME-INDUCED TOXICITY 647leucine, branched-chain acyl-CoA dehydrogenase for isoleucine,
isobutyryl-CoA dehydrogenase for valine, and glutaryl-CoA
dehydrogenase for lysine), and choline oxidation (DMGDH
and SDH) (Swigonova et al., 2009). In order to assess the
degree to which these enzymes were affected by EGME, we
performed a detailed examination of the metabolomic data with
the focus on the rest of enzymes in this family: glutaryl-CoA
dehydrogenase, isobutyryl-CoA dehydrogenase, and enzymes
of the fatty acid b-oxidation pathway. As a consequence, there
was clear evidence that this family of enzymes was indeed
broadly inhibited by EGME.
In the liver, both glutarylcarnitine (Fig. 5) and isobutyr-
ylglycine (Supplementary data) were increased signiﬁcantly at
day 14 of the 100 mg/kg EGME group. These changes were
consistent with the inhibition of glutaryl-CoA dehydrogenase
and isobutyryl-CoA dehydrogenase, respectively, leading to
the conversion of the CoA intermediates to their carnitine or
glycine esters. In the fatty acid b-oxidation pathway, several
species of fatty acid–derived carnitines were not altered
signiﬁcantly (Supplementary data). However, it is worth noting
that the most signiﬁcant biochemical sources for butyrylgly-
cine, butyrylcarnitine, and ethylmalonate are derived from fatty
acid b-oxidation rather than isoleucine degradation. Increases
of butyrylglycine, butyrylcarnitine, and ethylmalonate have been
regarded as hallmarks of inhibition of fatty acid b-oxidation
because of short-chain acyl-CoA dehydrogenase deﬁciency (van
Maldegem et al.,2 0 0 6 ).
The conclusion that EGME inhibits the primary ﬂavoprotein
dehydrogenase reactions is supported by published studies on
genetic disorders of acyl-CoA dehydrogenases in human. In
patients with multiple acyl-CoA dehydrogenase deﬁciency
(MADD), primary ﬂavoprotein dehydrogenase reactions are
impaired. Although the clinical features of MADD can vary
among patients, they always manifest themselves with muscle,
liver, heart, and congenital anomalies (Ghisla and Thorpe,
2004; Kim and Miura, 2004; Olsen et al., 2007). The urinary
and serum proﬁles of MADD patients are found to share
remarkable similarities with the ones observed in this study.
It has been well established that elevated dimethylglycine
and sarcosine (Burns et al., 1998; Goodman et al., 1980),
ethylmalonate, butyrylcarnitine, butyrylglycine (Amendt et al.,
1987; Bhala et al., 1995; Birkebaek et al., 2002; Jethva et al.,
2008; Koeberl et al., 2003; Przyrembel et al., 1976; van
Maldegem et al., 2006), 3-hydroxy-2-ethylpropionate, isobu-
tyrylcarnitine, 2-methylbutyrylcarnitine, 2-methylbutyrylgly-
cine, and glutarate (Andresen et al., 2000; Bennett et al.,
1994; Bonafe et al., 2000; Korman, 2006; Korman et al., 2005;
Tanaka et al., 1966; Vockley and Ensenauer, 2006) are
hallmarks in patients with varying degrees of MADD.
For the primary ﬂavoprotein dehydrogenases, the reducing
equivalents are transferred sequentially to the electron transfer
ﬂavoprotein (ETF), ETF-ubiquinone oxidoreductase (ETF:QO),
FIG. 4. Leucine metabolism and the box plots of leucine catabolites altered
by EGME treatment. Asterisk represents statistically signiﬁcant to the control
group.
FIG. 5. Lysine degradation pathway and the box plot of glutarylcarnitine
in the liver. Asterisk represents statistically signiﬁcant to the control group.
648 TAKEI ET AL.ubiquinone pool, and ﬁnally to bc1 complex (complex III)
(Lenaz, 2001). The molecular mechanism of MADD has been
demonstrated to be the consequence of mutations in either the
gene encoding ETF or the ETF:QO (Goodman et al., 2002;
Loehr et al., 1990). Thus, it is plausible that the inhibition of
ﬂavoprotein dehydrogenase reactions by EGME could be
mediated by disruptions of FAD-mediated electron transfer. It
is not yet clear that, however, how EGME might act in this
cascade of events that involve FAD reduction and the sub-
sequent oxidation. It is possible that EGME reduces the
interaction of ETF with the acyl-CoA dehydrogenase’s FAD or
between ETF and the EFT:QO. Future experiments to assess
EGME’s effect on the electron transfer steps using in vitro
assays may shed light on EGME’s precise site of action.
Alternatively, the possibility also exists that EGME’s action
upon ﬂavoprotein dehydrogenase reactions could be indirect. It
has been reported that MAA, the active metabolite of EGME
(Johanson, 2000), can inhibit histone deacetylase activity (Wade
et al.,2 0 0 8 ). Interestingly, the activity of LCAD, a primary
ﬂavoprotein dehydrogenase, can be increased by sirtuin-3,
an nicotinamide adenine dinucleotide dependent deacetylase
(Hirschey et al.,2 0 1 0 ). However, it remains unclear the degree
to which MAA can impact protein acetylation beyond the
histones.
The biochemical pathways utilizing ﬂavoprotein dehydro-
genases play critical biological functions in fatty acid
b-oxidation, BCAA catabolism, and choline oxidation. Dis-
ruption of these functions could conceivably lead to deleterious
outcomes. The choline oxidation pathway is a major source of
methionine, the precursor of S-adenosyl methionine, which is a
key methyl donor for many methylation reactions (Zeisel, 2006).
An interesting consequence of disrupted choline oxidation was
the accumulation of sarcosine (Fig. 2). The biological role of
sarcosine had been long ignored, except as a product of the
overﬂow methylation reaction. However, sarcosine was recently
found to mediate prostate cancer progression and regulate various
processes associated with cell proliferation and invasiveness
(Sreekumar et al.,2 0 0 9 ). It is plausible that the elevation of the
deleterious metabolite sarcosine may further mediate and escalate
EGME-induced toxicological consequences.
Collectively, the data strongly suggest that the inhibition of
ﬂavoprotein dehydrogenase enzyme family to be the mode of
action of EGME-induced toxicity. However, we do not want to
completely eliminate the possibility that alternative mecha-
nisms may exist for the biochemical perturbations observed in
this study. The EGME-induced accumulation of various metab-
olites could be because of the upregulations of their biosyn-
thetic enzymes. For example, the increases of dimethylglycine
and sarcosine can be explained by the enhanced activities from
betaine methyltransferase and glycine N-methyltransferase,
respectively. It would be worthwhile to study the impact of
EGME on the activities and expression levels of the enzymes in
the choline oxidation and BCAA metabolic pathways.
In this study, we also identiﬁed several metabolites indi-
cating cell and tissue damage by the EGME treatment at day 14
of the 100 mg/kg dose. Creatine biosynthesis was signiﬁcantly
elevated (Fig. 6). Creatine mediates high-energy phosphate
transport between sites of ATP production and ATP consump-
tion. Alterations of creatine biosynthesis, either overproduction
or deﬁciency, are known to produce pathological consequences
(Wyss and Kaddurah-Daouk, 2000). Dihydrouracil, pyroglut-
amine, and hydroxyproline were likely associated with DNA
FIG. 6. Creatine biosynthesis and the box plots of its metabolites altered by EGME treatment. Asterisk represents statistically signiﬁcant to the control group.
AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine.
MODE OF ACTION OF EGME-INDUCED TOXICITY 649breakdown, protein degradation, and tissue damage, respec-
tively. Ophthalmate is a marker for glutathione biosynthesis
(Soga et al., 2006). The decreased ophthalmate levels sug-
gested that glutathione production was inhibited by the EGME
treatment. In addition, N,N-dimethylarginine (ADMA), a marker
for oxidative stress (Beltowski and Kedra, 2006), was elevated
by EGME treatment (Fig. 7). These results are consistent with
published ﬁndings that genes related with oxidative stress were
upregulated by EGME (Fukushima et al.,2 0 0 5 ; Syed and Hecht,
1998; Wang and Chapin, 2000).
In summary, we performed an untargeted metabolomic
analysis of serum, urine, liver, and testes collected from rats
treated with EGME. Based on the results observed, we propose
that the mode of action of EGME-induced toxicity is mediated
through the inhibition of primary ﬂavoprotein dehydrogenases.
The disruption of key biochemical pathways utilizing the
ﬂavoprotein dehydrogenases in BCAA metabolism, fatty acid
b-oxidation, and choline oxidation, alone or in conjunction
with downsteam events such as sarcosine accumulation and
alteration of creatine biosynthesis, may precipitate the tissue and
cell damages observed as a consequence of EGME exposure.
SUPPLEMENTARY DATA
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